Company Profile
Nexpring Health is a USA-based global provider of assisted reproductive technology (ART) equipment, consumables, and media, headquartered in Beverly, Massachusetts, USA. Established in 2024 through the carve-out of Cook Reproductive Health and the take-private of Hamilton Thorne Ltd., the company operates as a privately held portfolio company of Astorg, led by Chief Executive Officer Wil Boren. Nexpring Health serves fertility clinics, embryologists, and research laboratories globally, leveraging more than 40 years of combined reproductive medicine expertise.
Core Products ＆ Technologies
CASA Systems ＆ Sperm Analysis
• SCA SCOPE: AI-driven computer-assisted sperm analysis for human motility, morphology, and DNA fragmentation
• SCA Production: Modular CASA platform for animal breeding, toxicology, and livestock reproductive management
• MetaClass: Karyotyping and FISH analysis systems for clinical cytogenetics
Precision Laser ＆ Imaging Systems
• LYKOS: Infrared laser for zona pellucida drilling and embryo biopsy in IVF procedures
• XYRCOS: Advanced laser platform for stem cell research and developmental biology
• OOsight Imaging: High-resolution optical systems for embryo and cell visualization
IVF Lab Equipment ＆ Media
• Incubators ＆ Workstations: Controlled-environment systems for embryo culture and micromanipulation
• GM501 Media Family: Comprehensive cell culture media for IVF and ART protocols
• Vitrification ＆ Culture Media: Advanced media solutions for embryo cryopreservation and development
Consumables ＆ AI Solutions
• ART Consumables: Embryo transfer catheters, oocyte retrieval needles, and single-use disposables
• Alife Embryo Assessment: AI-powered embryo ranking integrated with laser and imaging workflows
• MIM Fertility EMBRYOAID: AI embryo assessment tool deployed across Nexpring Health platforms
Market Position ＆ Certifications
Nexpring Health holds a leading global position in the ART consumables and equipment market, competing with Vitrolife and CooperSurgical. Key strengths include:
• 40+ years of combined reproductive medicine heritage across unified brands
• Comprehensive portfolio: One of the broadest ART solution sets spanning media, lasers, CASA, and cytogenetics
• Regulatory compliance: CE marked, FDA registered, and ISO certified across group manufacturing facilities
• AI integration: Strategic partnerships with Alife Health and MIM Fertility for next-generation embryo assessment
• Global reach: Direct sales and specialized distribution partners serving fertility professionals worldwide
Corporate Timeline
2024 — Formed via carve-out of Cook Reproductive Health and take-private acquisition of Hamilton Thorne Ltd.
2025 — Completed integration of FUJIFILM Irvine Scientific＇s ART and cytogenetics product portfolio
2025 — Officially launched Nexpring Health brand, uniting Cook, Hamilton Thorne, Planer, Gynemed, Microptic, and others
2026 — Invested in May Health to advance novel PCOS-related infertility treatment technology
2026 — Operates as a global ART leader with integrated media, equipment, and AI-driven solutions
Target Markets ＆ Applications
• Human Fertility ＆ IVF Clinics: End-to-end ART solutions from sperm analysis to embryo transfer and cryopreservation
• Animal Breeding ＆ Conservation: CASA and cryopreservation tools for livestock, equine, and endangered species programs
• Reproductive Research ＆ Toxicology: Sperm analysis platforms and media for pharmaceutical and developmental biology research
• Clinical Cytogenetics ＆ Diagnostics: Karyotyping, FISH, and cell genetic analysis systems for diagnostic labs
Contact Information
Global Headquarters
Address: 100 Cummings Center, Suite 465E, Beverly, MA 01915, USA
Website: www.nexpringhealth.com
Parent Company / Investor
Astorg
Address: Luxembourg, Grand Duchy of Luxembourg
Stock: Privately held (Astorg portfolio company)
Website: www.astorg.com
Investor Information: www.astorg.com/investments/nexpring-health
